相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Giovanni B. Frisoni et al.
NATURE REVIEWS NEUROSCIENCE (2022)
The synaptic marker neurogranin as a disease state biomarker in Alzheimer's disease: a systematic review and meta-analysis
Zhibin Wang et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2022)
Female specific risk factors for the development of Alzheimer's disease neuropathology and cognitive impairment: Call for a precision medicine approach
Chinedu Udeh-Momoh et al.
AGEING RESEARCH REVIEWS (2021)
A review on omics-based biomarkers discovery for Alzheimer's disease from the bioinformatics perspectives: Statistical approach vs machine learning approach
Mei Sze Tan et al.
COMPUTERS IN BIOLOGY AND MEDICINE (2021)
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
N. J. Ashton et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework
E. E. Wolters et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
A. Leuzy et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Gerard N. Bischof et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update
Marina Boccardi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis
Kristopher M. Kirmess et al.
CLINICA CHIMICA ACTA (2021)
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
Tim West et al.
MOLECULAR NEURODEGENERATION (2021)
An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease
Christopher Clark et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Critical Appraisal of Amyloid Lowering Agents in AD
Boris Decourt et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2021)
Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies
Andrea Pilotto et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases
Henrik Zetterberg
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Bruno Dubois et al.
LANCET NEUROLOGY (2021)
Cognitive reserve and Alzheimer's biological continuum: clues for prediction and prevention of dementia
Alessandro Martorana et al.
MINERVA MEDICA (2021)
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Harald Hampel et al.
NATURE REVIEWS NEUROLOGY (2021)
Anti-Cholinergic Derangement of Cortical Metabolism on 18F-FDG PET in a Patient with Frontotemporal Lobar Degeneration Dementia: A Case of the TREDEM Registry
Maurizio Gallucci et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease
Marco Canevelli et al.
JOURNAL OF PERSONALIZED MEDICINE (2020)
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Gill Livingston et al.
LANCET (2020)
Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease
Samantha Budd Haeberlein et al.
Alzheimers & Dementia (2020)
Alzheimer's disease: from basic science to precision medicine approach
Gianluigi Forloni
BMJ NEUROLOGY OPEN (2020)
The role of gut microbiota in pathogenesis of Alzheimer's disease
M. Bostanciklioglu
JOURNAL OF APPLIED MICROBIOLOGY (2019)
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson et al.
JAMA NEUROLOGY (2019)
Overlap Between Frontotemporal Dementia and Dementia with Lewy Bodies: A Treviso Dementia (TREDEM) Registry Case Report
Maurizio Gallucci et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler et al.
NEUROLOGY (2019)
Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF
Marco Canevelli et al.
FRONTIERS IN AGING NEUROSCIENCE (2019)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Biomarkers as drug development tools: discovery, validation, qualification and use
Virginia B. Kraus
NATURE REVIEWS RHEUMATOLOGY (2018)
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Harald Hampel et al.
NATURE REVIEWS NEUROLOGY (2018)
The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie
Giulia M. Sancesario et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia
Ron L. H. Handels et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology
Marina Boccardi et al.
NEUROBIOLOGY OF AGING (2017)
Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Valentina Garibotto et al.
NEUROBIOLOGY OF AGING (2017)
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Konstantinos Chiotis et al.
NEUROBIOLOGY OF AGING (2017)
Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Mara ten Kate et al.
NEUROBIOLOGY OF AGING (2017)
Clinical validity of presynaptic dopaminergic imaging with 123I- ioflupane and noradrenergic imaging with 123I- MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework
Ida Sonni et al.
NEUROBIOLOGY OF AGING (2017)
Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Niklas Mattsson et al.
NEUROBIOLOGY OF AGING (2017)
Microbiota and neurodegenerative diseases
Moira Marizzoni et al.
CURRENT OPINION IN NEUROLOGY (2017)
Consensus classification of posterior cortical atrophy
Sebastian J. Crutch et al.
ALZHEIMERS & DEMENTIA (2017)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack et al.
NEUROLOGY (2016)
Current Thinking on the Mechanistic Basis of Alzheimer's and Implications for Drug Development
C. Ising et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease
Cristina Valcarcel-Nazco et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2014)
Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium
Maria C. Carrillo et al.
ALZHEIMERS & DEMENTIA (2013)
A review on cholinesterase inhibitors for Alzheimer's disease
Preet Anand et al.
ARCHIVES OF PHARMACAL RESEARCH (2013)
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42
Niklas Mattsson et al.
BIOMARKERS IN MEDICINE (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Marilyn S. Albert et al.
ALZHEIMERS & DEMENTIA (2011)
Classification of primary progressive aphasia and its variants
M. L. Gorno-Tempini et al.
NEUROLOGY (2011)
Revising the definition of Alzheimer's disease: a new lexicon
Bruno Dubois et al.
LANCET NEUROLOGY (2010)
Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2007)
Evidence base of clinical diagnosis - The architecture of diagnostic research
DL Sackett et al.
BRITISH MEDICAL JOURNAL (2002)